Volume 68, Issue 5, Pages (November 2005)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 11, Pages (June 2006)

Advertisements

Reduced renal function in patients with simple renal cysts

Nina Vasavada, Rajiv Agarwal Kidney International

Volume 54, Issue 4, Pages (October 1998)

Volume 69, Issue 11, Pages (June 2006)

Volume 54, Issue 2, Pages (August 1998)

Volume 64, Issue 4, Pages (October 2003)

Plasma sodium and hypertension

Diagnosis and Management of Chronic Kidney Disease

Sushrut S. Waikar, Venkata S. Sabbisetti, Joseph V. Bonventre

Volume 64, Pages S72-S77 (November 2003)

Furosemide stimulates macula densa cyclooxygenase-2 expression in rats

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Volume 66, Issue 4, Pages (October 2004)

Volume 59, Issue 1, Pages (January 2001)

Hiroyuki Kobori, Lisa M. Harrison-Bernard, L. Gabriel Navar

Volume 58, Issue 1, Pages (July 2000)

High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury D.P. Gabriel, J.T. Caramori,

Volume 55, Issue 1, Pages (January 1999)

Methotrexate in the urine

Is it cerebral or renal salt wasting?

Volume 76, Issue 3, Pages (August 2009)

Volume 88, Issue 6, Pages (December 2015)

Comorbidity and confounding in end-stage renal disease

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load

Proinflammatory effects of iron sucrose in chronic kidney disease

Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion Lynda A. Frassetto, Eileen Nash,

Volume 70, Issue 11, Pages (December 2006)

Volume 54, Issue 5, Pages (November 1998)

Hyaluronan increases glomerular cyclooxygenase-2 protein expression in a p38 MAP- kinase–dependent process Marjorie E. Dunlop, Ph.D., Evelyne E. Muggli

Volume 87, Issue 2, Pages (February 2015)

Lane J. Brunner, William M. Bennett, Dennis R. Koop

COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex Klaus Höcherl, Christoph Schmidt,

Volume 68, Issue 6, Pages (December 2005)

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 67, Issue 1, Pages (January 2005)

Albumin-like material in urine

The third World Kidney Day: Looking back and thinking forward

Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression Klaus Höcherl, Frieder Kees, Bernhard K. Krämer,

Volume 64, Pages S72-S77 (November 2003)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier

Reduced renal function in patients with simple renal cysts

Counteracting progression of renal disease: A look into the future

Volume 78, Issue 5, Pages (September 2010)

Volume 56, Issue 5, Pages (November 1999)

Volume 74, Issue 5, Pages (September 2008)

Volume 74, Issue 9, Pages (November 2008)

A man with a hole in his penis

Homocysteine, renal function, and risk of cardiovascular disease

Volume 54, Issue 4, Pages (October 1998)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 82, Issue 9, Pages (November 2012)

Volume 74, Issue 9, Pages (November 2008)

Phosphate binders on iron basis: A new perspective?

Organ transplantation goes to the movies

Volume 58, Issue 3, Pages (September 2000)

Volume 69, Issue 1, Pages (January 2006)

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Is complement a target for therapy in renal disease?

Volume 65, Issue 4, Pages (April 2004)

Volume 69, Issue 11, Pages (June 2006)

Volume 62, Issue 5, (November 2002)

Aldosterone and potassium secretion by the cortical collecting duct

Volume 61, Issue 4, Pages (April 2002)

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Martina Franz, Wolfgang Woloszczuk,

Presentation transcript:

Volume 68, Issue 5, Pages 2197-2207 (November 2005) Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers Dirk O. Stichtenoth, Verena Marhauer, Dimitrios Tsikas, Frank-Mathias Gutzki, Jurgen C. Frolich Kidney International Volume 68, Issue 5, Pages 2197-2207 (November 2005) DOI: 10.1111/j.1523-1755.2005.00676.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Effects of celecoxib 200mg twice a day (b.i.d.), indomethacin 50mg three times a day (t.i.d.), or placebo on plasma renin activity on day 5 of treatment before (pre) and 5, 10, 30, 60, and 120 minutes after furosemide 20mg intravenously. Mean ± SE (N = 16). *P < 0.05; **P < 0.001 versus placebo, same time point; †P < 0.05; ††P <0.001 versus prefurosemide, same medication. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Effects of celecoxib 200mg twice a day (b.i.d.), indomemacin 50mg three times a day (t.i.d.), or placebo on plasma aldosterone concentration on day 5 of treatment before (pre) and 5, 10, 30, 60, and 120 minutes after 20mg intravenously. Mean ± SE (N = 16). *P < 0.05; **P < 0.001 versus placebo, same time point; †P < 0.05; ††P <0.001 versus prefurosemide, same medication. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Effects of celecoxib 200mg twice a day (b.i.d.) (▪), indomethacin 50mg three times a day (t.i.d.) (Δ), or placebo (○) on potassium (A), sodium (B), and creatinine (C) concentration in serum on day 5 of treatment before, 5, 10, 30, 60, and 120 minutes after 20mg furosemide intravenously. Mean ± SE (N = 16). *P < 0.05; **P < 0.001 versus placebo, same time point; †P < 0.05; ††P <0.001 versus before furosemide, same medication. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Effects of celecoxib 200 twice a day (b.i.d.), indomethacin 50mg three times a day (t.i.d.), or placebo on prostaglandin E2 (PGE2) excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17) **P < 0.001 versus placebo; #P < 0.05 vs. celecoxib. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Effects of celecoxib 200mg twice a day (b.i.d.), indomethacin 50 three times a day (t.i.d.), or placebo on 7α-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid (PGE-M) excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17). **P < 0.001 versus placebo; #P < 0.05 versus celecoxib. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Effects of celecoxib 200mg twice a day (b.i.d.), indomethacin 50mg three times a day (t.i.d.), or placebo on 2,3-dinor-6-keto-PGF1α and 2,3-dinor-thromboxane B2 (TxB2) excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17). **P < 0.001 versus placebo; ##P < 0.001 versus celecoxib. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 7 Effects of celecoxib 200mg twice a day (b.i.d.), indomethacin 50mg three times a day (t.i.d.), or placebo on 2,3-dinor-6-keto-PGF1α excretion in 24-hour urine on day 4 of treatment. Mean ± SE (N = 17). *P < 0.05 versus placebo. Kidney International 2005 68, 2197-2207DOI: (10.1111/j.1523-1755.2005.00676.x) Copyright © 2005 International Society of Nephrology Terms and Conditions